EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in Somatostatin Receptor-Targeting Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors: Biological Rationale, Combination Strategies, and Clinical Perspectives

Hana Bakr iD, Amin Al-Awar iD, Johan K E Spetz iD, Eva B Forssell-Aronsson iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27198709 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Hana Bakr und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, SE-413 45 Gothenburg, Sweden. Hauptthemen laut MEDLINE: Receptors, Somatostatin, Neuroendocrine Tumors, Radiopharmaceuticals. Die Arbeit nennt 281 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council, Swedish Cancer Society, Swedish government ALF agreement.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) are the most common subtype of NETs, and their incidence continues to increase worldwide. Many NETs express somatostatin receptors (SSTRs), enabling molecular imaging and treatment with radiolabeled somatostatin analogs (SSTAs). [177Lu]Lu-DOTATATE is an established treatment for advanced SSTR-positive NETs, but complete and durable responses remain uncommon. This review summarizes current clinical experience with [177Lu]Lu-DOTATATE and emerging SSTR-targeting radiopharmaceuticals and examines strategies to improve PRRT efficacy. Treatment may be enhanced at several interconnected steps, including increasing receptor availability and tumor targeting, improving radiopharmaceutical uptake and absorbed dose, preventing repair of radiation-induced damage, suppressing cellular stress adaptation and survival, and promoting tumor cell elimination. These approaches include radiation priming and fractionation, somatostatin analog pretreatment, epigenetic modifiers, inhibitors of DNA repair and cellular survival pathways, immunotherapy, and chemotherapy-based combinations. PARP, DNA-PK, and HSP90 inhibitors and chemotherapy-based combinations have shown particularly strong preclinical or clinical evidence, whereas mTOR inhibitors, tyrosine kinase inhibitors, Hedgehog inhibitors, immunotherapy, NAMPT inhibitors, p53 stabilization, and epigenetic modifiers remain under investigation. Ongoing development of novel radiopharmaceuticals, personalized dosimetry, retreatment strategies, and rational combinations is expected to refine PRRT and improve outcomes for patients with NETs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, SomatostatinNeuroendocrine TumorsRadiopharmaceuticalsHumansAnimalsOctreotideRadioisotopesOrganometallic CompoundsCombined Modality Therapy

Stichwörter der Autor:innen

DNA damage repairlutatheralutetium-177personalized dosimetryradiopharmaceuticalsradiosensitizationsomatostatin receptor upregulationtargeted radionuclide therapytheranosticstreatment optimization

Substanzen

Receptors, SomatostatinRadiopharmaceuticalsOctreotideRadioisotopeslutetium Lu 177 dotatateOrganometallic Compounds

Autor:innen und Institutionen

  • Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, SE-413 45 Gothenburg, Sweden.
  • Sahlgrenska Center for Cancer Research, Sahlgrenska Academy, University of Gothenburg, SE-405 30 Gothenburg, Sweden.
  • Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Region Västra Götaland, SE-413 45 Gothenburg, Sweden.

ORCID-Profile: Hana Bakr, Amin Al-Awar, Johan K E Spetz, Eva B Forssell-Aronsson

Förderung

  • Swedish Research Council
  • Swedish Cancer Society
  • Swedish government ALF agreement
  • Jubileumskliniken Cancerfond
  • Sahlgrenska University Hospital Research Funds
  • Assar Gabrielsson Cancer Research Foundation
  • Herbert & Karin Jacobsson Foundation
  • Royal Society of Sciences and Letters in Gothenburg

Zitieren

APA

Bakr, H., Al-Awar, A., Spetz, J. K. E., & Forssell-Aronsson, E. B. (2026). Advances in Somatostatin Receptor-Targeting Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors: Biological Rationale, Combination Strategies, and Clinical Perspectives. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27198709

Vancouver

Bakr H, Al-Awar A, Spetz JKE, Forssell-Aronsson EB. Advances in Somatostatin Receptor-Targeting Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors: Biological Rationale, Combination Strategies, and Clinical Perspectives. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27198709

BibTeX
@article{Bakr2026,
  author = {Bakr, Hana and Al-Awar, Amin and Spetz, Johan K E and Forssell-Aronsson, Eva B},
  title = {Advances in Somatostatin Receptor-Targeting Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors: Biological Rationale, Combination Strategies, and Clinical Perspectives},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27198709}
}
Kostenlos starten →